3 Over-the-Counter Formulations Exporter, Cardiovascular and CNS Brand Leader and Contract Manufacturing Specialist Stocks With a Strong Future Roadmap: Marksans Pharma, Torrent Pharmaceuticals and Innova Captab

Marksans Pharma, Torrent Pharmaceuticals and Innova Captab: ROE of 12.9% to 25.5% and FY22 to FY26 revenue CAGR of 12.4% to 19.5%. Prices as of 26 Oct 2026.

Updated: 27 Oct 2026 • 12:12 pm

Posted by:

Quick Answer

The three OTC, specialty brand and contract pharma stocks to watch are Marksans Pharma, Torrent Pharmaceuticals and Innova Captab. Their return on equity ranges from 12.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 19.5%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Innova Captab has the fastest revenue growth at 19.5% a year. Prices are based on the 26 October 2026 close, and this article is educational, not investment advice.

OTC, specialty brand and contract pharma stocks give investors a way to track businesses that sit close to everyday demand in India. Marksans Pharma, Torrent Pharmaceuticals and Innova Captab cover an over-the-counter formulations exporter, a cardiovascular and CNS brand leader and a contract manufacturing specialist.

This list covers three OTC, specialty brand and contract pharma stocks with complete current figures: Marksans Pharma, Torrent Pharmaceuticals and Innova Captab. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

What Are OTC, Specialty Brand and Contract Pharma Stocks?

OTC, specialty brand and contract pharma stocks are listed drug makers that export over-the-counter products, lead in heart and brain therapies and make formulations for other brands. Their earnings depend on launches, plant quality, prescriptions and outsourcing demand.

OTC, Specialty Brand and Contract Pharma Stocks at a Glance

Company	CMP (Rs)	Market Cap (Rs Cr)	P/E	Industry P/E	ROE (%)	D/E
Marksans Pharma	296.65	12,994	24.9	35.7	13.8	0.11
Torrent Pharmaceuticals	4,550	173,079	80.3	36.0	25.5	1.79
Innova Captab	998.2	5,736	37.2	36.0	12.9	0.32

On valuation, Marksans Pharma trades at a P/E below the industry P/E, while Torrent Pharmaceuticals and Innova Captab trade above it, which reflects the growth the market already expects. Readers comparing OTC, specialty brand and contract pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in OTC, specialty brand and contract pharma stocks can use the coming numbers to test whether growth is holding.

Why Do OTC, Specialty Brand and Contract Pharma Stocks Have a Strong Roadmap in India?

OTC, specialty brand and contract pharma stocks have a strong roadmap in India because trusted brands, export demand for self-care products and outsourced manufacturing keep widening the revenue base.

Self-care exports. Over-the-counter products sell across developed markets.
Chronic therapies. Heart and brain brands retain prescribers.
Outsourced work. Other drug brands hire contract makers.

Why Marksans Pharma Features Among These OTC, Specialty Brand and Contract Pharma Stocks

Among the OTC, specialty brand and contract pharma stocks on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.

The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.

Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore.

Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.

What to watch: Track export growth, new product approvals and plant utilisation.

Why Torrent Pharmaceuticals Features Among These OTC, Specialty Brand and Contract Pharma Stocks

Among the UK and US formulation exporter shares on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.

Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.

In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.

Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.

Why Innova Captab Features Among These OTC, Specialty Brand and Contract Pharma Stocks

Among the three companies on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.

In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.

Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.

Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.

Marksans Pharma vs Torrent Pharmaceuticals vs Innova Captab on Key Financials

The table below sets the three OTC, specialty brand and contract pharma stocks side by side on revenue, profit and margin, using reported figures.

Company	FY22 Revenue (Rs Cr)	FY26 Revenue (Rs Cr)	Revenue CAGR (FY22-FY26)	FY26 Net Profit (Rs Cr)	FY26 Net Margin
Marksans Pharma	1,533	3,033	18.6%	420	13.8%
Torrent Pharmaceuticals	8,705	13,886	12.4%	2,138	15.4%
Innova Captab	803	1,637	19.5%	141	8.6%

Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Torrent Pharmaceuticals has the largest FY26 revenue at Rs 13,886 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with OTC, specialty brand and contract pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Company	Q1 FY26 Revenue (Rs Cr)	Q1 FY27 Revenue (Rs Cr)	Year-on-Year Growth
Marksans Pharma	626	866	38.5%
Torrent Pharmaceuticals	3,141	4,909	56.3%
Innova Captab	356	473	32.8%

Key Risks to Check Before Investing in OTC, Specialty Brand and Contract Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these OTC, specialty brand and contract pharma stocks, the main points are: Long-term UK and US formulation exporter shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

Regulatory checks. Plant inspections can affect approvals.
Price pressure. Generic prices abroad can fall.
Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter OTC, specialty brand and contract pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on OTC, Specialty Brand and Contract Pharma Stocks

OTC, specialty brand and contract pharma stocks work best when investors track growth, valuation and return on equity side by side. Marksans Pharma, Torrent Pharmaceuticals and Innova Captab each have a clear plan to grow. Based on the 26 October 2026 close, Marksans Pharma trades at Rs 296.65, Torrent Pharmaceuticals at Rs 4,550 and Innova Captab at Rs 998.2. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these OTC, specialty brand and contract pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track OTC, specialty brand and contract pharma stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are OTC, specialty brand and contract pharma stocks?

Ans. OTC, specialty brand and contract pharma stocks are listed drug makers that export over-the-counter products, lead in heart and brain therapies and make formulations for other brands. Their earnings depend on launches, plant quality, prescriptions and outsourcing demand. This list looks at three of them, Marksans Pharma, Torrent Pharmaceuticals and Innova Captab, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.

Which OTC, specialty brand and contract pharma stocks are covered in this list?

Ans. This list covers Marksans Pharma, Torrent Pharmaceuticals and Innova Captab. Based on the 26 October 2026 close, Marksans Pharma traded at Rs 296.65, Torrent Pharmaceuticals at Rs 4,550 and Innova Captab at Rs 998.2. Their return on equity ranges from 12.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 19.5%.

Why do OTC, specialty brand and contract pharma stocks have a strong future roadmap in India?

Ans. OTC, specialty brand and contract pharma stocks have a strong roadmap in India because trusted brands, export demand for self-care products and outsourced manufacturing keep widening the revenue base. The main drivers are as follows. Self-care exports. Over-the-counter products sell across developed markets. Chronic therapies. Heart and brain brands retain prescribers. Outsourced work. Other drug brands hire contract makers. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Marksans Pharma performed financially?

Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.

How has Torrent Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

How has Innova Captab performed financially?

Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What risks should investors check before buying OTC, specialty brand and contract pharma stocks?

Ans. Investors should check a few risks before buying OTC, specialty brand and contract pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of OTC, specialty brand and contract pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.